CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0805 (clinicaltrials.gov NCT No: NCT00967044)
Title:Phase I/II of Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients with Relapsed and Refractory Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:LBH589 "B" (oral); Panobinostat; RAD001
Study Status:Terminated
Study Description:The goal of Phase 1 of this clinical research study is to learn the highest
tolerable dose of the combination of LBH589 (panobinostat) and RAD001
(everolimus) that can be given to patients with relapsed or refractory
lymphoma. The safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:LBH589 "B" (oral)
Panobinostat
RAD001
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Novartis
Return Visit:Screening, Baseline, Day 1, 2, 3 of every cycle, Day 4 of every other cycle,
Day 5 and 26 of cycle 1 , End of Treatment and Followup
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults